Nurse Practitioner · Charlotte, NC
NPI
1275932048
Since 2014
Specialty
Nurse Practitioner
Code 363L00000X
Group practices
1
Medicare group memberships
Hospitals
1
Hospital affiliations
1021 Morehead Medical Dr, Ste A
Charlotte, NC, 28204
Phone (980) 442-2000
Groups this clinician bills Medicare through
Medicare paid, 2024
$19K
331 services
Medicare patients, 2024
164
Average age 71
Drug cost, 2024
$17.8M
1,428 prescriptions
Company payments, 2025
$181
From 2 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Ami P Ndiaye was code 99214 (office e&m - established), 248 times for 128 patients. In total Ami P Ndiaye billed 331 services in 8 codes, and Medicare paid $19K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2024-07-15.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Facility | 248 | 128 | $56.46 | $14K |
| 38222 Other Organ Systems | Facility | 33 | 33 | $43.49 | $1,435 |
| 99214 Office E&M - Established | Office | 22 | 15 | $77.97 | $1,715 |
By year: 2022 $20K for 329 services; 2023 $23K for 376 services; 2024 $19K for 331 services.
Medicare prescription drug claims, 2024
In 2024, the drug Ami P Ndiaye prescribed most often to Medicare patients was Lenalidomide, with 355 prescriptions and refills. In total Ami P Ndiaye wrote 1,428 Medicare prescriptions that cost $17.8M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Lenalidomide Generic | 355 | 355 | 88 | $5.0M |
| Revlimid Lenalidomide | 323 | 323 | 107 | $5.9M |
| Pomalyst Pomalidomide | 199 | 199 | 53 | $4.5M |
| Acyclovir Generic | 73 | 158 | 34 | $1,555 |
| Ninlaro Ixazomib Citrate | 49 | 49 | 12 | $625K |
| Dexamethasone Generic | 46 | 52 | 24 | $673 |
| Potassium Chloride Generic | 44 | 84 | 20 | $832 |
| Venclexta Venetoclax | 38 | 38 | Under 11 | $591K |
| Brukinsa Zanubrutinib | 31 | 31 | Under 11 | $448K |
| Gabapentin Generic | 24 | 44 | 13 | $633 |
| Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim | 23 | 27 | Under 11 | $120 |
| Xpovio Selinexor | 18 | 18 | Under 11 | $559K |
| Omeprazole Generic | 14 | 37 | Under 11 | $323 |
| Oxycodone Hcl Generic | 14 | 14 | Under 11 | $183 |
| Tramadol Hcl Generic | 12 | 13 | Under 11 | $45 |
Brand drugs: - claims; generic drugs: 734 claims; opioid claims: 27.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Ami P Ndiaye $181 ($181 in general payments such as food, travel and fees) from 2 companies. The largest payer was Janssen Biotech, Inc. with $116.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.